Welcome to the Laura Heiser Lab
The research laboratory of Laura Heiser, Ph.D., is focused on identifying predictors of drug response and resistance, using novel imaging techniques to identify phenotypic changes associated with molecular aberrations and therapeutic response, and studying the influence of the microenvironment on cancer cells. In all of this research, the lab uses well-integrated experimental and computational approaches to understand the complexity of cancer. Because this work is necessarily multidisciplinary in nature, the lab frequently collaborate with diverse teams of scientists, as illustrated by involvement in the NIH LINCS Consortium, NCI Cancer Systems Biology Consortium (CSBC), and DREAM Project.
Heiser Lab news
- Bucher E, Claunch CJ, Hee D, Smith RL, Devlin K, Thompson W, Korkola JE, Heiser LM. Annot: a Django-based sample, reagent, and experiment metadata tracking system. BMC Bioinformatics. 2019 Nov 1;20(1):542. PMID: 31675914.
- Niepel M, Hafner M, Mills CE, Subramanian K, Williams EH, Chung M, Gaudio B, Barrette AM, Stern AD, Hu B, Korkola JE, LINCS Consortium, Gray JW, Birtwistle MR*, Heiser LM*, Sorger PK*. A multi-center study on the reproducibility of drug response assays in mammalian cell lines. Cell Systems. 2019 Jul 24;9(1):35-48.e5. PMID: 31302153.
- Coleman DJ, Gao L, King CJ, Schwartzman J, Urrutia J, Sehrawat A, Tayou J, Balter A, Burchard J, Chiotti KE, Derrick DS, Sun D, Xia Z, Heiser LM*, Alumkal JJ*. BET bromodomain inhibition blocks the function of a critical AR-independent master regulator network in lethal prostate cancer. Oncogene. 2019 Apr 17. PMID: 30996246.